The DESTINY-Lung01 trial is an ongoing phase II study of T-DXd in patients with non-squamous NSCLC overexpressing HER2 or with HER2-activating mutation (NCT03505710). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.